

Liste de publications de Carine Van Lint

5.1.3. - Parties d'ouvrages collectifs

2014

1. Bouchat, S., Van Driessche, B., & **Van Lint, C.** (2014). Transcription (initiation, regulation, elongation). In *Encyclopedia of AIDS*. Springer: Hope, T. Richman, D. Stevenson, M.
2. Colin, L., Verdin, E., & **Van Lint, C.** (2014). HIV-1 chromatin, transcription, and the regulatory protein Tat. In E. Vicenzi & G. Poli (Eds.), *Methods in molecular biology, Vol. 1087. Human Retroviruses* (pp. 85-101). Humana press.(Methods and Protocols).

1999

3. Bex, F., Burny, A., Van Den Broeke, A., & **Van Lint, C.** (1999). Virus infection, animal. In T. E. Creighton (Ed.), *Encyclopedia of Molecular Biology* (pp. 2750-2759). John Wiley and Sons Inc.(A Wiley-Interscience Publication).

5.1.4. et 5.1.5. - Articles dans des revues scientifiques avec comité de lecture

Accepté pour publication

1. Bouchat, S., Delacourt, N., Kula, A., Darcis, G., Van Driessche, B., Corazza, F., Gatot, J.-S., Melard, A., Vanhulle, C., Kabeya, K., Pardons, M., Avettand, V., Clumeck, N., De Wit, S., Rohr, O., Rouzioux, C., & **Van Lint, C.** (2015). Sequential Treatment with 5-aza-2'deoxycytidin and Desacetylase Inhibitors Reactivates HIV-1. *EMBO molecular medicine*.

2015

2. Sauter, D., Hotter, D., Van Driessche, B., Stürzel, C. M., Kluge, S. F., Wildum, S., Yu, H., Baumann, B., Wirth, T., Plantier, J.-C. J., Leoz, M. M., Hahn, B. H., **Van Lint, C.**, & Kirchhoff, F. F. (2015). Differential Regulation of NF- κ B-Mediated Proviral and Antiviral Host Gene Expression by Primate Lentiviral Nef and Vpu Proteins. *Cell reports*, 10, 586-599. doi:10.1016/j.celrep.2014.12.047
3. Kumar, A., Darcis, G., **Van Lint, C.**, & Herbein, G. (2015). Epigenetic control of HIV-1 post integration latency: implications for therapy. *Clinical Epigenetics*, 7(1), 103. doi:10.1186/s13148-015-0137-6
4. Darcis, G., Kula, A., Bouchat, S., Fujinaga, K., Corazza, F., Ait-Ammar, A., Delacourt, N., Melard, A., Kabeya, K., Vanhulle, C., Van Driessche, B., Gatot, J.-S., Cherrier, T., Pianowski, L. F., Gama, L., Schwartz, C., Vila, J., Burny, A., Clumeck, N., Moutschen, M., De Wit, S., Peterlin, M., Rouzioux, C., Rohr, O., & **Van Lint, C.** (2015). An In-Depth Comparison of Latency-Reversing Agent Combinations in Various in vitro and ex vivo HIV-1 Latency Models Identified Bryostatins-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. *PLoS pathogens*, 11(7), e1005063. doi:10.1371/journal.ppat.1005063
5. Thelie, A., Desiderio, S., Hanotel, J., Quigley, I., Van Driessche, B., Rodari, A., Borromeo, M., Kricha, S., Lahaye, F., Croce, J., Cerda-Moya, G., Ordonez-Fernandez, J., Bolle,

B., Lewis, K., Sander, M., Pierani, A., Schubert, M., Johnson, J., Kintner, C., Pieler, T., **Van Lint, C.**, Henningfeld, K. A., Bellefroid, E., & Van Campenhout, C. (2015). Prdm12 specifies V1 interneurons through cross-repressive interactions with Dbx1 and Nkx6 genes in Xenopus. *Development*, *142*(19), 3416-3428. doi:10.1242/dev.121871

2014

6. Eilebrecht, S., Le Douce, V., Roclet, R., Targat, B., Hallay, H., Van Driessche, B., Schwartz, C., Robette, G., **Van Lint, C.**, Rohr, O., & Benecke, A. (2014). HMGA1 recruits CTIP2-repressed P-TEFb to the HIV-1 and cellular target promoters. *Nucleic acids research*, *42*(8), 4962-4971. doi:10.1093/nar/gku168
7. Hanotel, J., Bessodes, N., Thelie, A., Hedderich, M., Parain, K., Van Driessche, B., Brandão De Oliveira, K., Kricha, S., Jorgensen, M. C., Grapin-Botton, A., Serup, P., **Van Lint, C.**, Perron, M., Pieler, T., Henningfeld, K. A., & Bellefroid, E. (2014). The Prdm13 histone methyltransferase encoding gene is a Ptf1a-Rbpj downstream target that suppresses glutamatergic and promotes GABAergic neuronal fate in the dorsal neural tube. *Developmental biology*, *386*(2), 340-357. doi:10.1016/j.ydbio.2013.12.024
8. Colin, L., Verdin, E., & **Van Lint, C.** (2014). HIV-1 chromatin, transcription, and the regulatory protein tat. *Methods in molecular biology*, *1087*, 85-101. doi:10.1007/978-1-62703-670-2_8

2013

9. Cherrier, T., Le Douce, V., Eilebrecht, S., Riclet, R., Marban, C., Dequiedt, F., Goumon, Y., Paillart, J.-C., Mericskay, M., Parlakian, A., Bausero, P., Abbas, W., Herbein, G., Kurdistani, S., Grana, X., Van Driessche, B., Candolfi, E., Schwartz, C., Benecke, A., **Van Lint, C.**, & Rohr, O. (2013). CTIP2 is a negative regulator of P-TEFb. *Proceedings of the National Academy of Sciences of the United States of America*, *110*(31), doi: 10.1073/pnas.1220136110, 12655-60. doi:10.1073/pnas.1220136110
10. **Van Lint, C.**, Bouchat, S., & Marcello, A. (2013). HIV-1 transcription and latency: an update. *Retrovirology*, *10*, 67. doi:10.1186/1742-4690-10-67

2012

11. Le Douce, V., Colin, L., Redel, L., Cherrier, T., Herbein, G., Aunis, D., Rohr, O., **Van Lint, C.**, & Schwartz, C. (2012). LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. *Nucleic acids research*, *40*, 1904-1915. doi:10.1093/nar/gkr857
12. Bouchat, S., Gatot, J.-S., Kabeya, K., Cardona, C., Colin, L., Herbein, G., De Wit, S., Clumeck, N., Lambotte, O., Rouzioux, C., Rohr, O., & **Van Lint, C.** (2012). Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients. *AIDS*, *26*(12), 1473-1482. doi:10.1097/QAD.0b013e32835535f5
13. The International AIDS Society Scientific Working Group on HIV Cure., Deeks, S., Autran, B., Berkhout, B., Benkirane, M., Cairns, S., Chomont, N., Chun, T.-W., Churchill, M., Mascio, M. D., Katlama, C., Lafeuillade, A., Landay, A., Lederman, M., Lewin, S. R., Maldarelli, F., Margolis, D., Markowitz, M., Martinez-Picado, J., Mullins, J. I., Mellors, J., Moreno, S., O'Doherty, U., Palmer, S., Penicaud, M.-C., Peterlin, M., Poli, G., Routy, J.-P., Rouzioux, C., Silvestri, G., Stevenson, M., Telenti, A., **Van Lint, C.**, Verdin, E., Woolfrey,

A., Zaia, J., & Barré-Sinoussi, F. (2012). Towards an HIV cure: a global scientific strategy. *Nature reviews. Immunology*, 12(8), 607-614. doi:10.1038/nri3262

14. Simonis, N., Rual, J.-F., Lemmens, I., Boxus, M., Hirozane-Kishikawa, T., Gatot, J.-S., Dricot, A., Hao, T., Vertommen, D., Legros, S., Daakour, S., Klitgord, N., Martin, M., Willaert, J.-F., Dequiedt, F., Navratil, V., Cusick, M. E., Burny, A., **Van Lint, C.**, Hill, D. E., Tavernier, J., Kettmann, R., Vidal, M., & Twizere, J.-C. (2012). Host-pathogen interactome mapping for HTLV-1 and -2 retroviruses. *Retrovirology*, 9, 26. doi:10.1186/1742-4690-9-26

2011

15. Colin, L., Dekoninck, A., Reichert, M., Calao, M., Merimi, M., Van Den Broeke, A., Vierendeel, V., Cleuter, Y., Burny, A., Rohr, O., & **Van Lint, C.** (2011). Chromatin disruption in the promoter of Bovine Leukemia Virus during transcriptional activation. *Nucleic acids research*, 39, 9559-9573. doi:10.1093/nar/gkr671
16. Vandurm, P., Guiguen, A., Cauvin, C., Georges, B., Le Van, K., Michaux, C., Cardona, C., Mbemba, G., Mouscadet, J.-F., Hevesi, L., **Van Lint, C.**, & Wouters, J. (2011). Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition. *European journal of medicinal chemistry*, 46(5), 1749-1756. doi:10.1016/j.ejmech.2011.02.028
17. Lens, Z., Dewitte, F., **Van Lint, C.**, De Launoit, Y., Villeret, V., & Verger, A. (2011). Purification of SUMO-1 modified I#B# and complex formation with NF-#B. *Protein expression and purification*. doi:10.1016/j.pep.2011.06.009
18. Legros, S., Boxus, M., Gatot, J.-S., **Van Lint, C.**, Kruys, V., Kettmann, R., Twizere, J.-C., & Dequiedt, F. (2011). The HTLV-1 Tax protein inhibits formation of stress granules by interacting with histone deacetylase 6. *Oncogene*, 30(38), 4050-4062. doi:10.1038/onc.2011.120
19. Colin, L., Vandenhoudt, N., De Walque, S., Van Driessche, B., Bergamaschi, A., Martinelli, V., Cherrier, T., Vanhulle, C., Guiguen, A., David, A., Burny, A., Herbein, G., Pancino, G., Rohr, O., & **Van Lint, C.** (2011). The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for viral replication. *PloS one*, 6(4), e19084. doi:10.1371/journal.pone.0019084

2010

20. Redel, L., Le Douce, V., Cherrier, T., Marban, C., Janossy, A., Aunis, D., **Van Lint, C.**, Rohr, O., & Schwartz, C. (2010). HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. *Journal of leukocyte biology*, 87, 575-588. doi:10.1189/jlb.0409264
21. Trono, D., **Van Lint, C.**, Rouzioux, C., Verdin, E., Barré-Sinoussi, F., Chun, T.-W., & Chomont, N. (2010). HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. *Science*, 329(5988), 174-180. doi:10.1126/science.1191047
22. Lens, Z., Dewitte, F., Monté, D., Baert, J.-L., Bompard, C., Sénéchal, M., **Van Lint, C.**, De Launoit, Y., Villeret, V., & Verger, A. (2010). Solution structure of the N-terminal transactivation domain of ERM modified by SUMO-1. *Biochemical and biophysical research communications*, 399(1), 104-110. doi:10.1016/j.bbrc.2010.07.049

23. Pierard, V., Guiguen, A., Colin, L., Wijmeersch, G., Vanhulle, C., Van Driessche, B., Dekoninck, A., Blazkova, J., Cardona, C., Merimi, M., Vierendeel, V., Calomme, C., Nguyen, T. L.-A., Nuttinck, M., Twizere, J.-C., Kettmann, R., Portetelle, D., Burny, A., Hirsch, I., Rohr, O., & **Van Lint, C.** (2010). DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: Potential involvement of direct inhibition of CREB/CREM/ATF transcription factor binding. *The Journal of biological chemistry*. doi:10.1074/jbc.M110.107607

2009

24. Reuse, S., Calao, M., Kabeya, K., Guiguen, A., Gatot, J.-S., Quivy, V., Vanhulle, C., Lamine, A., Vaira, D., Demonte, D., Martinelli, V., Veithen, E., Cherrier, T., Avettand, V., Poutrel, S., Piette, J., De Launoit, Y., Moutschen, M., Burny, A., Rouzioux, C., De Wit, S., Herbein, G., Rohr, O., Collette, Y., Lambotte, O., Clumeck, N., & **Van Lint, C.** (2009). Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. *PloS one*, 4(6), e6093. doi:10.1371/journal.pone.0006093
25. Vire, B., De Walque, S., Restouin, A., Olive, D., **Van Lint, C.**, & Collette, Y. (2009). Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. *PloS one*, 4(9), e7085. doi:10.1371/journal.pone.0007085
26. Colin, L., & **Van Lint, C.** (2009). Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. *Retrovirology*, 6, 111. doi:10.1186/1742-4690-6-111
27. Blazkova, J., Trejbalova, K., Gondois-Rey, F., Halfon, P., Philibert, P., Guiguen, A., Verdin, E., Olive, D., **Van Lint, C.**, Hejnar, J., & Hirsch, I. (2009). CpG methylation controls reactivation of HIV from latency. *PLoS pathogens*, 5(8), e1000554. doi:10.1371/journal.ppat.1000554
28. Cherrier, T., Suzanne, S., Redel, L., Calao, M., Marban, C., Samah, B., Mukerjee, R., Schwartz, C., Gras, G., Sawaya, B. E., Zeichner, S. L., Aunis, D., **Van Lint, C.**, & Rohr, O. (2009). p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. *Oncogene*, 28(38), 3380-3389. doi:10.1038/onc.2009.193
29. Le Van, K., Cauvin, C., De Walque, S., Georges, B., Boland, S., Martinelli, V., Demonte, D., Durant, F., Hevesi, L., & **Van Lint, C.** (2009). New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. *Journal of medicinal chemistry*, 52(12), 3636-3643. doi:10.1021/jm801438e
30. Vandurm, P., Cauvin, C., Guiguen, A., Georges, B., Le Van, K., Martinelli, V., Cardona, C., Mbemba, G., Mouscadet, J.-F., Hevesi, L., **Van Lint, C.**, & Wouters, J. (2009). Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl]-4-hydroxy-2-oxo-3-butenoic acid as HIV-1 integrase inhibitor. *Bioorganic & medicinal chemistry letters*, 19(16), 4806-4809. doi:10.1016/j.bmcl.2009.06.044
31. Ndlovu, M. N., **Van Lint, C.**, Van Wesemael, K., Callebert, P., Chalbos, D., Haegeman, G., & Vanden Berghe, W. (2009). Hyperactivated NF- κ B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. *Molecular and cellular biology*, 29(20), 5488-5504. doi:10.1128/MCB.01657-08

2008

32. Calao, M., Burny, A., Quivy, V., Dekoninck, A., & **Van Lint, C.** (2008). A pervasive role of histone acetyltransferases and deacetylases in an NF-kappaB-signaling code. *Trends in biochemical sciences*, 33(7), 339-349. doi:10.1016/j.tibs.2008.04.015
33. Mahlknecht, U., Dichamp, I., Varin, A., **Van Lint, C.**, & Herbein, G. (2008). NF-kappaB-dependent control of HIV-1 transcription by the second coding exon of Tat in T cells. *Journal of leukocyte biology*, 83(3), 718-727. doi:10.1189/jlb.0607405

2007

34. Quivy, V., De Walque, S., & **Van Lint, C.** (2007). Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies. *Sub-cellular biochemistry*, 41, 371-396.
35. Marban, C., Suzanne, S., Dequiedt, F., De Walque, S., Redel, L., **Van Lint, C.**, Aunis, D., & Rohr, O. (2007). Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. *EMBO journal*, 26(2), 412-423. doi:10.1038/sj.emboj.7601516
36. Horion, J., Gloire, G., El Mjiyad, N., Quivy, V., Vermeulen, L., Vanden Berghe, W., Haegeman, G., **Van Lint, C.**, Piette, J., & Habraken, Y. (2007). Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha. *The Journal of biological chemistry*, 282(21), 15383-15393. doi:10.1074/jbc.M609166200
37. Nguyen, T. L.-A., De Walque, S., Veithen, E., Dekoninck, A., Martinelli, V., De Launoit, Y., Burny, A., Harrod, R., & **Van Lint, C.** (2007). Transcriptional regulation of the bovine leukemia virus promoter by the cyclic AMP-response element modulator tau isoform. *The Journal of biological chemistry*, 282(29), 20854-20867. doi:10.1074/jbc.M703060200
38. Vandergeeten, C., Quivy, V., Moutschen, M., **Van Lint, C.**, Piette, J., & Legrand-Poels, S. (2007). HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA. *Biochemical pharmacology*, 73(11), 1738-1748. doi:10.1016/j.bcp.2007.02.011
39. Sharma, A., Awasthi, S., Harrod, C. K., Matlock, E. F., Khan, S., Xu, L., Chan, S., Yang, H., Thammavaram, C. K., Rasor, R. A., Burns, D. K., Skiest, D. J., **Van Lint, C.**, Girard, A.-M., McGee, M., Monnat, R. J., & Harrod, R. (2007). The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication. *The Journal of biological chemistry*, 282(16), 12048-12057. doi:10.1074/jbc.M608104200
40. Twizere, J.-C., Springael, J.-Y., Boxus, M., Burny, A., Dequiedt, F., Dewulf, J.-F., Duchateau, J., Portetelle, D., Urbain, P., **Van Lint, C.**, Green, P. L., Mahieux, R., Parmentier, M., Willems, L., & Kettmann, R. (2007). Human T-cell leukemia virus type-1 Tax oncoprotein regulates G-protein signaling. *Blood*, 109(3), 1051-1060. doi:10.1182/blood-2006-06-026781

2006

41. Mauen, S., Huvent, I., Raussens, V., Demonte, D., Baert, J.-L., Tricot, C., Ruyschaert, J. M., **Van Lint, C.**, Moguilevsky, N., & De Launoit, Y. (2006). Expression, purification, and

structural prediction of the Ets transcription factor ERM. *Biochimica et biophysica acta*, 1760(8), 1192-1201. doi:10.1016/j.bbagen.2006.03.007

42. Castellano, R., Vire, B., Pion, M., Quivy, V., Olive, D., Hirsch, I., **Van Lint, C.**, & Collette, Y. (2006). Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling: role of DNA methylation and protein acetylation suggest distinct mechanisms of transcriptional repression. *The Journal of biological chemistry*, 281(21), 14719-14728. doi:10.1074/jbc.M602373200

2005

43. Goffin, V., Demonte, D., Vanhulle, C., De Walque, S., De Launoit, Y., Burny, A., Collette, Y., & **Van Lint, C.** (2005). Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. *Nucleic acids research*, 33(13), 4285-4310. doi:10.1093/nar/gki720
44. Marban, C., Redel, L., Suzanne, S., **Van Lint, C.**, Lecestre, D., Chasserot-Golaz, S., Leid, M., Aunis, D., Schaeffer, E., & Rohr, O. (2005). COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. *Nucleic acids research*, 33(7), 2318-2331. doi:10.1093/nar/gki529
45. Desfosses, Y., Solis, M., Sun, Q., Grandvaux, N., **Van Lint, C.**, Burny, A., Gaignol, A., Wainberg, M. A., Lin, R., & Hiscott, J. (2005). Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. *Journal of virology*, 79(14), 9180-9191. doi:10.1128/JVI.79.14.9180-9191.2005
46. T'Sas, F., Brenner, C., Mauén, S., Putmans, P., Monté, D., **Van Lint, C.**, Moser, M., Baert, J.-L., & De Launoit, Y. (2005). Expression of the Ets transcription factor Erm is regulated through a conventional PKC signaling pathway in the Molt4 lymphoblastic cell line. *FEBS letters*, 579(1), 66-70. doi:10.1016/j.febslet.2004.11.052
47. Varin, A., Decrion, A.-Z., Sabbah, E., Quivy, V., Sire, J., **Van Lint, C.**, Roques, B. P., Aggarwal, B. B., & Herbein, G. (2005). Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. *The Journal of biological chemistry*, 280(52), 42557-42567. doi:10.1074/jbc.M502211200
48. Kim, Y.-S., Kim, J.-M., Jung, D.-L., Kang, J.-E., Lee, S., Kim, J. S., Seol, W., Shin, H.-C., Kwon, H. S., **Van Lint, C.**, Hernandez, N., & Hur, M.-W. (2005). Artificial zinc finger fusions targeting Sp1-binding sites and the trans-activator-responsive element potently repress transcription and replication of HIV-1. *The Journal of biological chemistry*, 280(22), 21545-21552. doi:10.1074/jbc.M414136200
49. Wong, K., Sharma, A., Awasthi, S., Matlock, E. F., Rogers, L., **Van Lint, C.**, Skiest, D. J., Burns, D. K., & Harrod, R. (2005). HIV-1 Tat interactions with p300 and PCAF transcriptional coactivators inhibit histone acetylation and neurotrophin signaling through CREB. *The Journal of biological chemistry*, 280(10), 9390-9399. doi:10.1074/jbc.M408643200

2004

50. Quivy, V., Calomme, C., Dekoninck, A., Demonte, D., Bex, F., Lamsoul, I., Vanhulle, C., Burny, A., & **Van Lint, C.** (2004). Gene activation and gene silencing: a subtle equilibrium. *Cloning and stem cells*, 6(2), 140-149. doi:10.1089/1536230041372454
51. **Van Lint, C.**, Quivy, V., Demonte, D., Chariot, A., Vanhulle, C., De Walque, S., Gaudray, G., Veithen, E., Bours, V., Piette, J., & Burny, A. (2004). Molecular mechanisms involved in HIV-1 transcriptional latency and reactivation: implications for the development of therapeutic strategies. *Bulletin et mémoires de l'Académie royale de médecine de Belgique*, 159(Pt 2), 176-189.
52. Goriely, S., **Van Lint, C.**, Dadkhah, R., Libin, M., De Wit, D., Demonte, D., Willems, F., & Goldman, M. (2004). A defect in nucleosome remodeling prevents IL-12(p35) gene transcription in neonatal dendritic cells. *The Journal of experimental medicine*, 199(7), 1011-1016. doi:10.1084/jem.20031272
53. Demonte, D., Quivy, V., Colette, Y., & **Van Lint, C.** (2004). Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. *Biochemical pharmacology*, 68(6), 1231-1238. doi:10.1016/j.bcp.2004.05.040
54. Quivy, V., & **Van Lint, C.** (2004). Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. *Biochemical pharmacology*, 68(6), 1221-1229. doi:10.1016/j.bcp.2004.05.039
55. Wong, K., Zhang, J., Awasthi, S., Sharma, A., Rogers, L., Matlock, E. F., **Van Lint, C.**, Karpova, T., McNally, J., & Harrod, R. (2004). Nerve growth factor receptor signaling induces histone acetyltransferase domain-dependent nuclear translocation of p300/CREB-binding protein-associated factor and hGCN5 acetyltransferases. *The Journal of biological chemistry*, 279(53), 55667-55674. doi:10.1074/jbc.M408174200
56. **Van Lint, C.** (2004). Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. *AIDS reviews*, 6(1), 61-62.
57. Nguyen, T. L.-A., Calomme, C., Wijmeersch, G., Nizet, S., Veithen, E., Portetelle, D., De Launoit, Y., Burny, A., & **Van Lint, C.** (2004). Deacetylase inhibitors and the viral transactivator TaxBLV synergistically activate bovine leukemia virus gene expression via a cAMP-responsive element- and cAMP-responsive element-binding protein-dependent mechanism. *The Journal of biological chemistry*, 279(33), 35025-35036. doi:10.1074/jbc.M404081200
58. Calomme, C., Dekoninck, A., Nizet, S., Adam, E., Nguyen, T. L.-A., Van Den Broeke, A., Willems, L., Kettmann, R., Burny, A., & **Van Lint, C.** (2004). Overlapping CRE and E box motifs in the enhancer sequences of the bovine leukemia virus 5' long terminal repeat are critical for basal and acetylation-dependent transcriptional activity of the viral promoter: implications for viral latency. *Journal of virology*, 78(24), 13848-13864. doi:10.1128/JVI.78.24.13848-13864.2004

2003

59. Viatour, P., Legrand-Poels, S., **Van Lint, C.**, Warnier, M., Merville, M.-P., Gielen, J., Piette, J., Bours, V., & Chariot, A. (2003). Cytoplasmic I kappa B alpha increases NF-kappa B-independent transcription through binding to histone deacetylase (HDAC) 1

- and HDAC3. *The Journal of biological chemistry*, 278(47), 46541-46548. doi:10.1074/jbc.M306381200
60. Adam, E., Quivy, V., Bex, F., Chariot, A., Collette, Y., Vanhulle, C., Schoonbroodt, S., Goffin, V., Nguyen, T. L.-A., Gloire, G., Carrard, G., Friguet, B., De Launoit, Y., Burny, A., Bours, V., Piette, J., & **Van Lint, C.** (2003). Potentiation of tumor necrosis factor-induced NF-kappa B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I kappa B alpha. *Molecular and cellular biology*, 23(17), 6200-6209.
61. Goriely, S., Demonte, D., Nizet, S., De Wit, D., Willems, F., Goldman, M., & **Van Lint, C.** (2003). Human IL-12(p35) gene activation involves selective remodeling of a single nucleosome within a region of the promoter containing critical Sp1-binding sites. *Blood*, 101(12), 4894-4902. doi:10.1182/blood-2002-09-2851
62. Szydal, M., Cleuter, Y., Beskorwayne, T., Bagnis, C., **Van Lint, C.**, Kerkhofs, P., Burny, A., Martiat, P., Griebel, P., & Van Den Broeke, A. (2003). Disruption of B-cell homeostatic control mediated by the BLV-Tax oncoprotein: association with the upregulation of Bcl-2 and signaling through NF-kappaB. *Oncogene*, 22(29), 4531-4542. doi:10.1038/sj.onc.1206546
63. Pouillon, V., Hascakova-Bartova, R., Pajak, B., Adam, E., Bex, F., Dewaste, V., **Van Lint, C.**, Leo, O., Erneux, C., & Schurmans, S. (2003). Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development. *Nature immunology*, 4(11), 1136-1143. doi:10.1038/ni980
64. Callens, N., Baert, J.-L., Sunesen, M., **Van Lint, C.**, & De Launoit, Y. (2003). Transcriptional regulation of the murine *brca2* gene by CREB/ATF transcription factors. *Biochemical and biophysical research communications*, 312(3), 702-707. doi:10.1016/j.bbrc.2003.10.176
65. Harrod, R., Nacsa, J., **Van Lint, C.**, Hansen, J., Karpova, T., McNally, J., & Franchini, G. (2003). Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. *The Journal of biological chemistry*, 278(14), 12310-12318. doi:10.1074/jbc.M211167200
66. Maurer, P., T'Sas, F., Coutte, L., Callens, N., Brenner, C., **Van Lint, C.**, De Launoit, Y., & Baert, J.-L. (2003). FEV acts as a transcriptional repressor through its DNA-binding ETS domain and alanine-rich domain. *Oncogene*, 22(21), 3319-3329. doi:10.1038/sj.onc.1206572
67. Varin, A., Manna, S. K., Quivy, V., Decrion, A.-Z., **Van Lint, C.**, Herbein, G., & Aggarwal, B. B. (2003). Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis. *The Journal of biological chemistry*, 278(4), 2219-2227. doi:10.1074/jbc.M209622200
68. Dekoninck, A., Calomme, C., Nizet, S., De Launoit, Y., Burny, A., Ghysdael, J., & **Van Lint, C.** (2003). Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat. *Oncogene*, 22(19), 2882-2896. doi:10.1038/sj.onc.1206392

2002

69. Calomme, C., Nguyen, T. L.-A., De Launoit, Y., Kiermer, V., Droogmans, L., Burny, A., & **Van Lint, C.** (2002). Upstream stimulatory factors binding to an E box motif in the R region of the bovine leukemia virus long terminal repeat stimulates viral gene expression. *The Journal of biological chemistry*, 277(11), 8775-8789. doi:10.1074/jbc.M107441200
70. Quivy, V., Adam, E., Collette, Y., Demonte, D., Chariot, A., Vanhulle, C., Berkhout, B., Castellano, R., De Launoit, Y., Burny, A., Piette, J., Bours, V., & **Van Lint, C.** (2002). Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-kappaB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. *Journal of virology*, 76(21), 11091-11103.
71. Quivy, V., & **Van Lint, C.** (2002). Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system. *Biochemical pharmacology*, 64(5-6), 925-934. doi:10.1016/S0006-2952(02)01152-8
72. Iordanskiy, S., Iordanskaya, T., Quivy, V., **Van Lint, C.**, & Bukrinsky, M. (2002). B-oligomer of pertussis toxin inhibits HIV-1 LTR-driven transcription through suppression of NF-kappaB p65 subunit activity. *Virology*, 302(1), 195-206. doi:10.1006/viro.2002.1618
73. Castellano, R., **Van Lint, C.**, Peri, V., Veithen, E., Morel, Y., Costello, R., Olive, D., & Collette, Y. (2002). Mechanisms regulating expression of the tumor necrosis factor-related light gene. Role of calcium-signaling pathway in the transcriptional control. *The Journal of biological chemistry*, 277(45), 42841-42851. doi:10.1074/jbc.M207689200
74. Demonte, D., **Van Lint, C.**, & Burny, A. (2002). La thérapie génique. *Revue Médicale de Bruxelles*, 23(4), A331-A334.
75. Callens, N., Dumont, M., Begue, A., **Van Lint, C.**, Baert, J. L., Simard, J., & De Launoit, Y. (2002). Genomic organization and expression of the mouse Brca2 gene. *Mammalian genome*, 13(7), 352-358.
76. Gatot, J.-S., Callebaut, I., **Van Lint, C.**, Demonte, D., Kerkhofs, P., Portetelle, D., Burny, A., Willems, L., & Kettmann, R. (2002). Bovine leukemia virus SU protein interacts with zinc, and mutations within two interacting regions differently affect viral fusion and infectivity in vivo. *Journal of virology*, 76(16), 7956-7967.
77. Merezak, C., Reichert, M., **Van Lint, C.**, Kerkhofs, P., Portetelle, D., Willems, L., & Kettmann, R. (2002). Inhibition of histone deacetylases induces bovine leukemia virus expression in vitro and in vivo. *Journal of virology*, 76(10), 5034-5042.
- 2001**
78. Burny, A., Demonte, D., & **Van Lint, C.** (2001). Les gènes: moteurs de la vie et de la maladie. *Bulletin et mémoires de l'Académie royale de médecine de Belgique*, 156(10-12), 533-544.
79. Bentires-Alj, M., Dejardin, E., Viatour, P., **Van Lint, C.**, Froesch, B., Reed, J. C., Merville, M.-P., & Bours, V. (2001). Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. *Oncogene*, 20(22), 2805-2813. doi:10.1038/sj.onc.1204343
80. Merezak, C., Pierreux, C., Adam, E., Lemaigre, F., Rousseau, G., Calomme, C., **Van Lint, C.**, Christophe, D., Kerkhofs, P., Burny, A., Kettmann, R., & Willems, L. (2001).

Suboptimal enhancer sequences are required for efficient Bovine Leukemia Virus propagation in vivo: implications for viral latency. *Journal of Virology*, 75(15), 6977-6988. doi:10.1128/JVI.75.15.6977-6988.2001

2000

81. **Van Lint, C.** (2000). Role of chromatin in HIV-1 transcriptional regulation. *Advances in pharmacology*, 48, 121-160.

1999

82. Kiernan, R. E., Vanhulle, C., Schiltz, L., Adam, E., Xiao, H., Maudoux, F., Calomme, C., Burny, A., Nakatani, Y., Jeang, K. T., Benkirane, M. M., & **Van Lint, C.** (1999). HIV-1 tat transcriptional activity is regulated by acetylation. *EMBO journal*, 18(21), 6106-6118. doi:10.1093/emboj/18.21.6106
83. Critchfield, J. W., Ho, O., Roberts, M., **Van Lint, C.**, Verdin, E., & Butera, S. T. (1999). Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency. *Antiviral chemistry & chemotherapy*, 10(5), 275-284.
84. Chariot, A., **Van Lint, C.**, Chapelier, M., Gielen, J., Merville, M.-P., & Bours, V. (1999). CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. *Oncogene*, 18(27), 4007-4014. doi:10.1038/sj.onc.1202776

1998

85. Kiermer, V., **Van Lint, C.**, Briclet, D., Vanhulle, C., Kettmann, R., Verdin, E., Burny, A., & Droogmans, L. (1998). An interferon regulatory factor binding site in the U5 region of the bovine leukemia virus long terminal repeat stimulates Tax-independent gene expression. *Journal of virology*, 72(7), 5526-5534.
86. Emiliani, S., Fischle, W., **Van Lint, C.**, Al-Abed, Y., & Verdin, E. (1998). Characterization of a human RPD3 ortholog, HDAC3. *Proceedings of the National Academy of Sciences of the United States of America*, 95(6), 2795-2800.
87. Emiliani, S., Fischle, W., Ott, M., **Van Lint, C.**, Amella, C. A., & Verdin, E. (1998). Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. *Journal of virology*, 72(2), 1666-1670.
88. Herbein, G., **Van Lint, C.**, Lovett, J., & Verdin, E. (1998). Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. *Journal of virology*, 72(1), 660-670.

1997

89. **Van Lint, C.**, Amella, C. A., Emiliani, S., John, M., Jie, T., & Verdin, E. (1997). Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. *Journal of virology*, 71(8), 6113-6127.

90. Ott, M., Emiliani, S., **Van Lint, C.**, Herbein, G., Lovett, J., Chirmule, N., McCloskey, T., Pahwa, S., & Verdin, E. (1997). Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. *Science*, 275(5305), 1481-1485.

1996

91. Emiliani, S., **Van Lint, C.**, Fischle, W., Paras, P., Ott, M., Brady, J., & Verdin, E. (1996). A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency. *Proceedings of the National Academy of Sciences of the United States of America*, 93(13), 6377-6381.
92. **Van Lint, C.**, Emiliani, S., Ott, M., & Verdin, E. (1996). Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. *EMBO journal*, 15(5), 1112-1120.
93. **Van Lint, C.**, Emiliani, S., & Verdin, E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. *Gene expression*, 5(4-5), 245-253.

1995

94. Verdin, E., & **Van Lint, C.** (1995). Internal transcriptional regulatory elements in HIV-1 and other retroviruses. *Cellular and molecular biology*, 41(3), 365-369.

1994

95. **Van Lint, C.**, Ghysdael, J., Paras, P., Burny, A., & Verdin, E. (1994). A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of human immunodeficiency virus type 1. *Journal of virology*, 68(4), 2632-2648.

1993

96. Verdin, E., Paraskevas, P., & **Van Lint, C.** (1993). Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. *EMBO journal*, 12(8), 3249-3259.

1991

97. **Van Lint, C.**, Burny, A., & Verdin, E. (1991). The intragenic enhancer of human immunodeficiency virus type 1 contains functional AP-1 binding sites. *Journal of virology*, 65(12), 7066-7072.

5.1.7. - Communications publiées lors de congrès ou colloques nationaux et internationaux

2015

1. Rodari, A., Van Driessche, B., Delacourt, N., Vanhulle, C., Burny, A., Van Den Broeke, A., Rohr, O., & **Van Lint, C.** (2015). In vivo characterisation of the BLV miRAN cluster. *Abstract of the 17th International Conference on Human Retrovirology : HTLV & related Viruses*.

2014

2. Robette, G., Van Driessche, B., Fauquenoy, S., Kula, A., Delacourt, N., Vanhulle, C., Schwarzer, C., Burny, A., Rohr, O., & **Van Lint, C.** (2014). Identification and characterization of new functional Sp1 sites located in the R region of the Human T-

lymphotropic Virus 1 (HTLV-1) Long Terminal Repeat: Alterations of Metabloci pathways as therapeutic targets. *Abstract of Metabolism 2014*.

3. Kula, A., Darcis, G., Bouchat, S., Kabeya, K., Delacourt, N., Vanhulle, C., Robette, G., Burny, A., Clumeck, N., Rohr, O., Moutschen, M., Rouzioux, C., De Wit, S., & **Van Lint, C.** (2014). Reactivation of postintegration HIV-1 latency : potential therapeutic approach to purge the viral reservoirs. *Abstract of Metabolism 2014*.

2013

4. **Van Lint, C.** (2013). HIV-1 reservoirs and epigenetic control of viral postintegration latency : implications for therapeutic interventions. *Abstract of HIVERA Think Tank Meeting*.
5. **Van Lint, C.** (2013). Approches moléculaires pour éliminer les réservoirs du VIH. *Abstract of Journées Québécoises VIH*.
6. **Van Lint, C.** (2013). HIV-1 reservoirs and epigenetic control of viral postintegration latency : implications for therapeutic interventions. *Abstract of IAS "Towards an HIV cure" Think Tank Meeting*.
7. **Van Lint, C.** (2013). Molecular mechanisms of HIV-1 post-integration latency. *Abstract of "30 years of HIV Science Symposium"*.
8. Darcis, L., Kula, A., Bouchat, S., Kabeya, K., Delacourt, N., Vanhulle, C., Gatot, J.-S., Vaira, D., Burny, A., Herbein, G., Clumeck, N., Rohr, O., Moutschen, M., Rouzioux, C., De Wit, S., & **Van Lint, C.** (2013). Synergistic activation of HIV-1 expression by compounds targeting the positive transcription elongation factor b (P-TEFb) and by inducers of the NF- κ B signaling pathway. *Abstract of EACS 2013*.
9. **Van Lint, C.**, Cherrier, T., Van Driessche, B., Vanhulle, C., Robette, G., Delacourt, N., Schwarzer, C., & Rohr, O. (2013). Dual role of the cellular cofactor CTIP2 in HIV-1 latency. *Abstract of 14th European AIDS conference*.
10. Van Driessche, B., Robette, G., Guiguen, A., Vanhulle, C., Burny, A., Rohr, O., & **Van Lint, C.** (2013). Identification and characterization of new functional Sp1 sites located in the R region of the Human T-lymphotropic Virus 1 (HTLV-1) Long Terminal Repeat. *Abstract of the 16th International Conference on Human Retrovirology : HTLV & related Viruses*.

2012

11. **Van Lint, C.** (2012). Comment cibler le réservoir ? *Abstract of 6ème Conférence Francophone VIH/SIDA (AFRAVIH)*.
12. **Van Lint, C.** (2012). Deciphering the HIV persistence. *Abstract of 17th International Symposium HIV & Emerging Infectious Diseases (ISHEID)*.
13. **Van Lint, C.** (2012). Epigenetic control of human immunodeficiency virus type 1 (HIV-1-) latency : implications for therapeutic interventions. *Abstract of the Belgian Microbiology Society Symposium "Posttranscriptional regulation and epigenetics in microorganisms"*.

2011

14. Anseau, E., Charron,, Guiguen, A., **Van Lint, C.**, Coppée, F., & Belayew, A. (2011). YY1 and MyoD are transcriptional activator and inhibitor, respectively, of the DUX4 gene that causes facioscapulohumeral muscular dystrophy (FSHD). *Abstract of International Congress of Myology*.
15. Robette, G., Van Driessche, B., Guiguen, A., Burny, A., Rohr, O., & **Van Lint, C.** (2011). Role of the cofactor CTIP2 (COUP-TF Interacting Protein 2) in the transcriptional repression of HTLV-1 (Human T-lymphotropic Virus 1). *Abstract of 15th International Conference on Human Retroviruses: HTLV and Related Viruses*.
16. Bouchat, S., Gatot, J.-S., Kabeya, K., Cardona, C., Colin, L., Bergamaschi, A., Lamine,, Herbein, G., De Wit, S., Clumeck, N., Lambotte, O., Rohr, O., & **Van Lint, C.** (2011). Reactivation of HIV-1 gene expression by histone methyltransferase or DNA methylation inhibitors. *6th IAS Conference on HIV Pathogenesis, Treatment and Prevention*.
17. Colin, L., Dekoninck, A., Reichert, M., Merimi, M., Van Den Broeke, A., Vierendeel, V., Cleuter, Y., Burny, A., Rohr, O., & **Van Lint, C.** (2011). 101. Chromatin disruption in the promoter of bovine leukemia virus during transcriptional activation. *Abstract of Meeting "Frontiers of Retrovirology*.
18. Bouchat, S., Gatot, J.-S., Kabeya, K., Cardona, C., Colin, L., Herbein, G., De Wit, S., Clumeck, N., Lambotte, O., Rouzioux, C., Rohr, O., & **Van Lint, C.** (2011). Reactivation of HIV-1 gene expression by DNA methylation or histone methyltransferase inhibitors. *Abstract of Meeting "Frontiers of Retrovirology 2011"*.
19. Van Driessche, B., Colin, L., Guiguen, A., Vanhulle, C., Blazkova, J., Cardona, C., Merimi, M., Nuttinck, M., Twizere, J.-C., Kettmann, R., Portetelle, D., Burny, A., Hirsch, I., Rohr, O., & **Van Lint, C.** (2011). DNA cytosine methylation in the Bovine Leukemia Virus promoter is associated with latency in a Lymphoma-derived B-cell line : potential involvement of direct inhibition of CREB/CREM/ATF binding. *Abstract of 15th International Conference on Human Retroviruses: HTLV and Related Viruses*.

2010

20. Colin, L., Dekoninck, A., Guiguen, A., Robette, G., Vierendeel, V., Reichert, M., Burny, A., Rohr, O., & **Van Lint, C.** (2010). Chromatin disruption in the promoter of bovine leukemia virus during transcriptional activation. *Abstract of Meeting "Epigenetic mechanisms in health and diseases"*.
21. Reuse, S., Colin, L., Calao, M., Kabeya, K., Gatot, J.-S., Bouchat, S., Guiguen, A., Vanhulle, C., Cardona, C., Lamine, A., Avettand, V., Rouzioux, C., De Wit, S., Herbein, G., Rohr, O., Collette, Y., Lambotte, O., Clumeck, N., & **Van Lint, C.** (2010). Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. *Abstract of AIDS 2010*.
22. Guiguen, A., Vandurm, P., Cauvin, C., George, B., Le Van, K., Martinelli, V., Cardona, C., Mbemba, G., Mouscadet, J.-F., Hevesi, L., **Van Lint, C.**, & Wouters, (2010). HIV-1 integrase inhibition by quinolone compounds: contribution to the rational design of new inhibitors. *Abstract of Forum de recherches fondamentales et cliniques sur le VIH*.

23. Boittiaux,, Braun, J., Stern,, Vandermess,, Van Driessche, B., Poupaert, J. H., Willems, L., **Van Lint, C.**, Lambert, D., & Wouters, (2010). Conception, synthèse et évaluation de composés à vocation épigénétique. *Abstract of Journée Télévie*.
24. Guiguen, A., Colin, L., Pierard, V., Wijmeersch, G., Vanhulle, C., Van Driessche, B., Dekoninck, A., Blazkova, J., Cardona, C., Merimi, M., Vierendeel, V., Calomme, C., Nguyen, T. L.-A., Nuttinck, M., Twizere, J.-C., Kettmann, R., Portetelle, D., Burny, A., Hirsch, I., Rohr, O., & **Van Lint, C.** (2010). DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: potential involvement of direct inhibition of cAMP-responsive element (CRE)-binding protein/CRE modulator/activation transcription factor binding. *Abstract of Meeting "Epigenetic mechanisms in health and diseases"*.

2009

25. Colin, L., Dekoninck, A., Guiguen, A., Vierendeel, V., Reichert, M., Burny, A., Rohr, O., & **Van Lint, C.** (2009). Chromatin disruption in the promoter of Bovine Leukemia Virus during transcriptional activation. *Abstract of "Retroviruses"*.
26. Reuse, S., Calao, M., Kabeya, K., Guiguen, A., Gatot, J.-S., Quivy, V., Vanhulle, C., Lamine, A., Vaira, D., Demonte, D., Martinelli, V., Veithen, E., Cherrier, T., Avettand, V., Poutrel, S., Piette, J., De Launoit, Y., Moutschen, M., Burny, A., Rouzioux, C., De Wit, S., Herbein, G., Rohr, O., Collette, Y., Lambotte, O., Clumeck, N., & **Van Lint, C.** (2009). Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. *Abstract of "Frontiers of Retrovirology : Complex retroviruses, retroelements and their hosts"*.
27. Vandenhoudt, N., De Walque, S., Van Driessche, B., Colin, L., Martinelli, V., Guiguen, A., Vanhulle, C., Burny, A., Herbein, G., Rohr, O., & **Van Lint, C.** (2009). The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. *Abstract of Meeting "Frontiers of Retrovirology : Complex retroviruses, retroelements and their hosts"*.

2008

28. Vandenhoudt, N., De Walque, S., Van Driessche, B., Colin, L., Guiguen, A., Martinelli, V., Vanhulle, C., Burny, A., Rohr, O., & **Van Lint, C.** (2008). The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. *Abstract of the meeting : « 2e Forum de recherches fondamentales et cliniques sur le VIH: Stratégies de contrôle du VIH nouvelles perspectives, nouvelles questions »*.
29. Reuse, S., Calao, M., Quivy, V., Demonte, D., Vaira, D., Vanhulle, C., Guiguen, A., Fort, E., Martinelli, V., De Wit, S., Kabeya, K., Moutschen, M., Piette, J., Avettand, V., Burny, A., Rouzioux, C., Clumeck, N., Rohr, O., Collette, Y., & **Van Lint, C.** (2008). HDAC inhibitors and the NF- κ B inducer prostratin cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. *EMBO Workshop "NF- κ B Network in Development and Disease"*.

2007

30. Calao, M., Reuse, S., Quivy, V., Demonte, D., Vanhulle, C., Veithen, E., Martinelli, V., De Wit, S., Kabeya, K., Moutschen, M., Vaira, D., Avettand, V., Burny, A., Rouzioux, C., Clumeck, N., Rohr, O., Collette, Y., & **Van Lint, C.** (2007). HDAC inhibitors and the NF- κ B inducer prostratin cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. *Abstract of the meeting: «Chromatin Structure and Function» (Abcam organization)*.

31. Dekoninck, A., Vierendeel, V., Reichert, M., Burny, A., Rohr, O., & **Van Lint, C.** (2007). Chromatin disruption in the promoter of Bovine Leukemia Virus during transcriptional activation. *Abstract of the meeting: «Chromatin Structure and Function» (Abcam organization).*

2006

32. Calao, M., Quivy, V., Demonte, D., Reuse, S., Vanhulle, C., Gaudray, G., De Wit, S., Kabeya, K., Hermans, P., Clumeck, N., Moutschen, M., Vaira, D., Habraken, Y., Chariot, A., Collette, Y., Burny, A., Piette, J., & **Van Lint, C.** (2006). HDAC inhibitors and NF- κ B inducers cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. *Abstract of Keystone Symposia Conference "NF- κ B: 20 years on the road from biochemistry to pathology.*
33. Quivy, V., Demonte, D., Horion, J., Reuse, S., Vanhulle, C., Gaudray, G., Calao, M., De Wit, S., Kabeya, K., Clumeck, N., Moutschen, M., Vaira, D., Burny, A., & **Van Lint, C.** (2006). HDAC inhibitors and NF- κ B inducers cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. *Abstract of ANRS, 1er Forum de recherches fondamentales et cliniques sur le VIH: du patient.*
34. Reuse, S., Quivy, V., Demonte, D., Vanhulle, C., Calao, M., De Walque, S., De Wit, S., Kabeya, K., Clumeck, N., Moutschen, M., Vaira, D., Burny, A., & **Van Lint, C.** (2006). HDAC inhibitors and NF- κ B inducers cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. *Abstract of the 2006 International Meeting of the Institute of Human Virology (10th anniversary).*
35. De Walque, S., Vanhulle, C., Vandenhoudt, N., Van Driessche, B., Burny, A., & **Van Lint, C.** (2006). Transcription factor binding sites in the pol gene intragenic region of HIV-1 are important for virus infectivity. *Abstract of the 2006 International Meeting of the Institute of Human Virology (10th anniversary).*

2005

36. Quivy, V., Demonte, D., Horion, J., Reuse, S., Vanhulle, C., Gaudray, G., Calao, M., De Wit, S., Kabeya, K., Hermans, P., Clumeck, N., Moutschen, M., Vaira, D., Habraken, Y., Chariot, A., Burny, A., Piette, J., Collette, Y., & **Van Lint, C.** (2005). HDAC inhibitors and NF- κ B inducers cooperate to reactivate latent HIV-1 proviruses in cellular reservoirs. *Abstract of the 2nd International Workshop on HIV Persistence during Therapy.*

2004

37. Demonte, D., Quivy, V., Vanhulle, C., Moutschen, M., Vaira, D., Hermans, P., De Wit, S., Burny, A., Piette, J., & **Van Lint, C.** (2004). Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. *Abstract of the Meeting « Chromatin structure and gene expression mechanisms as therapeutic targets».*
38. Quivy, V., Adam, E., Demonte, D., Bex, F., Collette, Y., Chariot, A., Vanhulle, C., Burny, A., Bours, V., Piette, J., & **Van Lint, C.** (2004). Potentiation of TNF α -induced NF- κ B activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of I κ B α . *Abstract of the Meeting « Chromatin structure and gene expression mechanisms as therapeutic targets».*
39. Calomme, C., Dekoninck, A., Nizet, S., Adam, E., Nguyen, T. L.-A., Van Den Broeke, A., Willems, L., Kettmann, R., Burny, A., & **Van Lint, C.** (2004). Overlapping CRE and E

box motifs in the Enhancer Sequences of the Bovine Leukemia Virus 5' Long Terminal Repeat are critical for basal and acetylation-dependent transcriptional activity of the viral promoter: implications for viral latency. *Abstract of the Meeting « Chromatin structure and gene expression mechanisms as therapeutic targets».*

40. Castellano, R., Vire, B., Quivy, V., Olive, D., **Van Lint, C.**, & Collette, Y. (2004). Active transcription of human TNFSF/CD95L and TNFSF14/Light genes involves distinct mechanisms of chromatin remodeling. *Abstract of the Meeting « Chromatin structure and gene expression mechanisms as therapeutic targets», Luxembourg, European Conference Center Kirchberg-Luxembourg.*
41. Ndlovu, M., Vanden Berghe, W., **Van Lint, C.**, & Haegeman, G. (2004). Analysis of chromatin dynamics at the interleukin 6 gene promoter and correlation with metastatic potential of breast carcinoma cells. *Abstract of the Meeting « Chromatin structure and gene expression mechanisms as therapeutic targets».*
42. Calomme, C., Dekoninck, A., Nguyen, T. L.-A., Willems, L., Kettmann, R., Burny, A., & **Van Lint, C.** (2004). Overlapping CRE and E box motifs in the enhancer sequences of the bovine leukemia virus 5' long terminal repeat are critical for basal and acetylation-dependent transcriptional activity of the viral promoter: implications for viral latency. *Abstract of the "HTLV European Research Network (HERN).*
43. Marban, C., Redel, L., Suzanne, S., Lecestre, D., Dequiedt, F., **Van Lint, C.**, Aunis, D., & Rohr, O. (2004). Inhibition of HIV-1 expression by CTIP2-mediated recruitment of HDAC activities to the Long Terminal Repeat. *Abstract of 2004 Keystone Symposium "Chromatin Structure and Function".*
44. Dekoninck, A., Calomme, C., Nizet, S., De Launoit, Y., Burny, A., Ghysdael, J., & **Van Lint, C.** (2004). Role of the transcription factor PU.1 and role of chromatin organization in the transcriptional regulation of the Bovine Leukemia Virus (BLV). *Abstract of the Meeting « Chromatin structure and gene expression mechanisms as therapeutic targets».*
45. Dekoninck, A., Calomme, C., De Launoit, Y., Burny, A., Ghysdael, J., & **Van Lint, C.** (2004). Identification and characterization of a PU.1/Spi-B binding site in the bovine leukemia virus long terminal repeat. *Abstract of the "HTLV European Research Network (HERN).*

2003

46. Nguyen, T. L.-A., Adam, E., Calomme, C., Nizet, S., Burny, A., De Launoit, Y., & **Van Lint, C.** (2003). Synergistic activation of the BLV promoter transcriptional activity by TaxBLV and inhibitors of deacetylases. *Abstract of the CSH Meeting on Mechanisms of Eukaryotic Transcription.*
47. Goffin, V., Demonte, D., Vanhulle, C., Collette, Y., Veithen-Fort,, Burny, A., & **Van Lint, C.** (2003). Characterization of the transcriptional enhancer located in the pol gene of HIV-1. *Abstract of the CSH Meeting on Mechanisms of Eukaryotic Transcription.*
48. Quivy, V., Adam, E., Bex, F., Chariot, A., Collette, Y., Vanhulle, C., Schoonbroodt, S., Goffin, V., Nguyen, T. L.-A., Gloire, G., Carrard, G., Friguet, B., De Launoit, Y., Burny, A., Bours, V., Piette, J., & **Van Lint, C.** (2003). Potentiation of TNFalpha-induced NF-kappaB activation by deacetylase inhibitors is associated with a delayed cytoplasmic

reappearance of I κ B α . *Abstract of the CSH Meeting on Mechanisms of Eukaryotic Transcription.*

49. Collette, Y., Quivy, V., Adam, E., Vire, B., Demonte, D., Olive, D., Burny, A., & **Van Lint, C.** (2003). Deacetylase inhibitors as candidate drugs to purge latently HIV-1-infected reservoirs in HAART patients? Mechanistic insights into regulation of viral replication by Deacetylase inhibitors. *Abstract of the 2nd IAS Conference on HIV Pathogenesis and Treatment.*
50. Demonte, D., Goffin, V., Vanhulle, C., Collette, Y., Veithen-Fort,, Burny, A., & **Van Lint, C.** (2003). The HIV-1 intragenic enhancer is important for viral replication. *Abstract of the 2003 International Meeting of the Institute of Human Virology.*
51. Demonte, D., Quivy, V., Adam, E., Moutschen, M., Hermans, P., Burny, A., Piette, J., & **Van Lint, C.** (2003). Deacetylase inhibitors: a new hope in eradication of HIV-1 latent reservoirs? *Abstract of the 1st International Workshop on HIV Persistence during Therapy.*
52. Dekoninck, A., Calomme, C., Nizet, S., De Launoit, Y., Burny, A., Ghysdael, J., & **Van Lint, C.** (2003). Identification and characterization of a PU.1/SPI-B binding site in the Bovine Leukemia Virus Long Terminal Repeat. *Abstract of the CSH Meeting on Mechanisms of Eukaryotic Transcription.*

2002

53. Quivy, V., Adam, E., Collette, Y., Burny, A., Piette, J., & **Van Lint, C.** (2002). Synergistic activation of HIV-1 promoter activity by NF-kappaB and inhibitors of deacetylases: implications for the development of therapeutic strategies. *Abstract of the Meeting « Cell signaling, transcription and translation as therapeutic targets ».*
54. Goffin, V., Demonte, D., Vanhulle, C., Collette, Y., Veithen-Fort,, Burny, A., & **Van Lint, C.** (2002). Functional analysis of the transcriptional enhancer located in the pol gene of HIV-1. *Abstract of the Meeting « Cell signaling, transcription and translation as therapeutic targets ».*
55. Nguyen, T. L.-A., Adam, E., Calomme, C., Nizet, S., Brenner, C., Burny, A., De Launoit, Y., & **Van Lint, C.** (2002). Synergistic activation of the BLV promoter transcriptional activity by TaxBLV and inhibitors of deacetylases. *Abstract of the Meeting « Controls of Gene Expression » of the Belgian Society of Biochemistry and Molecular Biology (BSBMB).*
56. Goffin, V., Demonte, D., Vanhulle, C., Collette, Y., Veithen-Fort,, Burny, A., & **Van Lint, C.** (2002). Characterization of the transcriptional enhancer located in the pol gene of HIV-1. *Abstract of the Meeting « Controls of Gene Expression » of the Belgian Society of Biochemistry and Molecular Biology (BSBMB).*
57. Calomme, C., Adam, E., Nguyen, T. L.-A., Dekoninck, A., Nizet, S., Burny, A., & **Van Lint, C.** (2002). Positive and negative regulation of Bovine Leukemia Virus gene expression by four E-box motifs. *Abstract of the Meeting « Controls of Gene Expression » of the Belgian Society of Biochemistry and Molecular Biology (BSBMB).*
58. Quivy, V., Adam, E., Collette, Y., Demonte, D., Chariot, A., Vanhulle, C., Berkhout, B., Castellano, R., De Launoit, Y., Burny, A., Piette, J., Bours, V., & **Van Lint, C.**

(2002). Synergistic activation of HIV-1 promoter activity by NF-kappaB and inhibitors of deacetylases: implications for the development of therapeutic strategies. *Abstract of the Meeting « Controls of Gene Expression » of the Belgian Society of Biochemistry and Molecular Biology (BSBMB)*.

59. Cauvin, C., Boland, S., Demonte, D., **Van Lint, C.**, & Durant, F. (2002). Quinoline-2,4(1H,3H)-diones as potential non nucleoside reverse transcriptase inhibitors. *Abstract of the meeting "Drug Hunting: new targets, new tools, new drugs" (one day symposium organised by the Medicinal Chemistry Division of the Société Royale de Chimie)*.
60. Adam, E., Quivy, V., Bex, F., Schoonbroodt, S., Burny, A., Bours, V., Piette, J., & **Van Lint, C.** (2002). Potentiation of TNF-induced NF-kB activation by deacetylase inhibitors is associated with a delay in the recovery of Ikbalpha. *Abstract of the Meeting « Cell signaling, transcription and translation as therapeutic targets »*.

2001

61. Quivy, V., Adam, E., Colette, Y., Burny, A., Piette, J., Bours, V., & **Van Lint, C.** (2001). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and deacetylase inhibitor, Trichostatin A (TSA). *Abstract of the 2001 International Meeting of the Institute of Human Virology, A Symposium on HIV-AIDS and Related Viral Carcinogenesis*.
62. Quivy, V., Adam, E., Colette, Y., Burny, A., Piette, J., Bours, V., & **Van Lint, C.** (2001). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and deacetylase inhibitor, Trichostatin A (TSA). *Abstract of the Cold Spring Harbor Laboratory: Mechanisms of Eukaryotic transcription*.
63. Adam, E., Quivy, V., Colette, Y., Burny, A., Piette, J., Bours, V., & **Van Lint, C.** (2001). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and deacetylase inhibitor, Trichostatin A (TSA). *Abstract des Conférences Jacques Monod: Signaling and control of the transcription*.
64. Quivy, V., Adam, E., Colette, Y., Burny, A., Piette, J., Bours, V., & **Van Lint, C.** (2001). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and deacetylase inhibitor, Trichostatin A (TSA). *Abstract of the NF-kB meeting: regulation, gene expression and disease*.
65. Calomme, C., Adam, E., Nguyen, T. L.-A., Dekoninck, A., Nizet, S., Burny, A., & **Van Lint, C.** (2001). Positive and negative regulation of Bovine Leukemia Virus gene expression by four E-box motifs. *Abstract of the Retroviruses Meeting*.
66. Gatot, J.-S., Callebaut, I., Demonte, D., Kerkhofs, P., Adam, E., Portetelle, D., Burny, A., **Van Lint, C.**, Willems, L., & Kettmann, R. (2001). Zinc-binding of BLV and HTLV-I SU glycoproteins. *Abstract of the 13th International Workshop on Retroviral Pathogenesis*.
67. Gatot, J.-S., Callebaut, I., **Van Lint, C.**, Demonte, D., Kerkhofs, P., Portetelle, D., Burny, A., Willems, L., & Kettmann, R. (2001). Use of Hydrophobic Cluster Analysis to localize a BLV SU zinc-binding peptide on a three-dimensional model predicted by interference to the Fr-MLV receptor-binding domain. *Abstract of the 1st conference of the FNRS Structural Biology Contact Group, Structure/Function Relationships in Proteins*.

2000

68. Quivy, V., Adam, E., Goffin, V., Vanhulle, C., Burny, A., & **Van Lint, C.** (2000). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and histone deacetylase inhibitor, Trichostatin A (TSA). *European Conference on Experimental AIDS Research (5th ECEAR)*.
69. **Van Lint, C.**, Kiernan, R. E., Vanhulle, C., Schiltz, L., Adam, E., Adam, A., Xiao, H., Maudoux, F., Calomme, C., Jeang, K. T., Nakatani, Y., Burny, A., & Benkirane, M. (2000). HIV-1 Tat transcriptional activity is regulated by acetylation (abstract 158). *Abstract of the 2000 Keystone Symposium on "Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology"*.
70. **Van Lint, C.**, Adam, E., Quivy, V., Goffin, V., Vanhulle, C., & Burny, A. (2000). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and histone deacetylase inhibitor, Trichostatin A (TSA). *Abstract of the 2000 International Meeting of the Institute of Human Virology, A Symposium on HIV-AIDS and Related Viral Carcinogenesis*.
71. Adam, E., Goffin, V., Vanhulle, C., Quivy, V., Verdin, E., Burny, A., & **Van Lint, C.** (2000). Synergistic activation of HIV-1 promoter transcriptional activity by NF-kB and histone deacetylase inhibitor, Trichostatin A (abstract 101). *Abstract of the 2000 Keystone Symposium on "Novel Biological Approaches to HIV-1 Infection Based on New Insights into HIV Biology"*.
72. **Van Lint, C.**, Benkirane, M. M., Nakatani, Y., Jeang, K. T., Verdin, E., & Burny, A. (2000). Transcriptional regulation of HIV-1 gene expression by acetylation of histones and non-histone proteins. *Abstract of the San Marino Conference "Highlights in Immunology, Oncology and Virology. AIDS, Cancer and Hepatitis: scientific and ethical challenges"*.
73. Calomme, C., Nguyen, T. L.-A., Kiermer, V., Droogmans, L., Burny, A., & **Van Lint, C.** (2000). Identification and characterization of a functional E-box motif in the R region of the Bovine Leukemia Virus Long Terminal repeat. *Abstract of the EMBL Transcription Meeting*.

1999

74. **Van Lint, C.**, Kiernan, R. E., Vanhulle, C., Schiltz, L., Adam, E., Xiao, M., Maudoux, F., Calomme, C., Jeang, K. T., Nakatani, Y., Burny, A., & Benkirane, M. (1999). Acetylation of Tat by p300 and P/CAF differentially modulates TAR RNA-binding and TAK association and is required for transcription. *Abstract of the Fourth European Conference on Experimental AIDS Research (4th ECEAR)*.
75. Kiernan, R. E., Vanhulle, C., Schiltz, L., Adam, E., Xiao, M., Maudoux, F., Calomme, C., Burny, A., Nakatani, Y., Jeang, K. T., **Van Lint, C.**, & Benkirane, M. (1999). Acetylation of Tat by p300 and P/CAF differentially modulates TAR RNA-binding and TAK association and is required for transcription. *Abstract of the Retroviruses Meeting. Cold Spring Harbor Laboratory*.
76. **Van Lint, C.**, Kiernan, R. E., Vanhulle, C., Schiltz, L., Adam, E., Xiao, M., Maudoux, F., Calomme, C., Jeang, K. T., Nakatani, Y., Burny, A., & Benkirane, M. (1999). Acetylation of Tat by p300 and P/CAF differentially modulates TAR RNA-binding and TAK association and is required for transcription. *Abstract of the 1999 International Meeting of the Institute of Human Virology, A Symposium on HIV/AIDS & Cancer Biology*.

77. Bex, F., Burny, A., Van Den Broeke, A., & **Van Lint, C.** (1999). Virus expression or virus latency: how to make the choice? *Abstract of the 1999 International Symposium on HIV, Leukemia, and Opportunistic Cancers.*

1998

78. Jackers, P., Garnier,, **Van Lint, C.**, Verdin, E., & Castronovo, V. (1998). Detection of DNaseI-hypersensitive sites in the human gene coding for the 37 kD laminin receptor precursor/p40 ribosomal associated protein. *Abstract of the 5th Euregional Oncology Meeting.*
79. Jackers, P., Garnier,, **Van Lint, C.**, Verdin, E., & Castronovo, V. (1998). Detection of DNaseI-hypersensitive sites in the human gene coding for the 37 kD laminin receptor precursor/p40 ribosomal associated protein. *Abstract of the Belgian Association for Cancer Research.*
80. **Van Lint, C.**, Amella, C. A., Emiliani, S., John,, Jie, T., Vanhulle, C., Burny, A., & Verdin, E. (1998). Transcription factor binding sites downstream of the transcription start site of HIV-1 are important for virus infectivity. *Abstract of the Third European Conference on Experimental AIDS Research (ECEAR).*

1997

81. Herbein, G., **Van Lint, C.**, Lovett, J., & Verdin, E. (1997). Direct induction of apoptosis by HIV-1 during infection of peripheral blood lymphocytes in vitro. *Abstract of the Keystone Symposium on Apoptosis and Programmed Cell Death (Abstract 130).*
82. Emiliani, S., **Van Lint, C.**, Spector,, Fischle, W., & Verdin, E. (1997). Cloning and characterization of a new human histone deacetylase, HD2. *Abstract of the Keystone Symposium on Functional Organization of the Nucleus.*
83. Kiermer, V., **Van Lint, C.**, Verdin, E., Burny, A., & Droogmans, L. (1997). Regulation of gene expression by the R-U5 region of Bovine leukemia virus genome. *Abstract of the Retroviruses Meeting. Cold Spring Harbor Laboratory.*
84. Emiliani, S., **Van Lint, C.**, Fischle, W., & Verdin, E. (1997). Cloning and characterization of a new human histone deacetylase, HDAC3. *Abstract of the Cold Spring Harbor Meeting on Mechanisms of Eukaryotic Transcription..*
85. **Van Lint, C.** (1997). Rôle de l'acétylation des histones dans la régulation transcriptionnelle des gènes de HIV-1. *Journées de Cancérologie Fondamentale et Clinique de l'Institut Bordet, Symposium de la Fondation MEDIC sous les auspices du F.N.R.S..*

1996

86. Verdin, E., **Van Lint, C.**, Emiliani, S., & Ott, M. (1996). Chromatin is an integral component of HIV-1 transcriptional repression and activation. *Abstract of the Keystone Symposium on Molecular and Cellular Biology "Molecular Biology of HIV".*
87. Emiliani, S., **Van Lint, C.**, Fischle, W., Paras, P., Ott, M., Brady, J., & Verdin, E. (1996). Mechanism of HIV-1 latency: the Tat-TAR axis is a crucial determinant of the latent phenotype. *Abstract of the Keystone Symposium on Molecular and Cellular Biology "Molecular Biology of HIV".*

88. Ott, M., Chirmule, N., Lovett, J., Mc Closkey,, **Van Lint, C.**, Emiliani, S., & Verdin, E. (1996). The HIV-1 Tat protein confers hypersensitivity for costimulation via the CD28 pathway. *Abstract of the Keystone Symposium on Molecular and Cellular Biology "Molecular Biology of HIV"*.
89. **Van Lint, C.**, John,, Amella, C. A., Emiliani, S., Ott, M., & Verdin, E. (1996). Binding sites for several transcription factors downstream of the transcription start site of HIV-1 are critical for virus infectivity. *Abstract of the 3rd Conference on Retroviruses and Opportunistic Infections*.
90. **Van Lint, C.**, Emiliani, S., Ott, M., & Verdin, E. (1996). Chromatin is an integral component of HIV-1 transcriptional repression and activation. *Abstract of the First European Conference on Experimental AIDS Research (ECEAR)*.
91. **Van Lint, C.**, John,, Amella, C. A., Emiliani, S., Ott, M., & Verdin, E. (1996). Binding sites for transcription factors downstream of the transcription start site of HIV-1 are critical for virus infectivity. *Abstract of the First European Conference on Experimental AIDS Research (ECEAR)*.
92. Ott, M., Chirmule, N., Lovett, J., Mc Closkey,, **Van Lint, C.**, Emiliani, S., Pahwa, S., & Verdin, E. (1996). The HIV-1 Tat protein confers hypersensitivity for costimulation via the CD28 pathway. *Abstract of the Keystone Symposium on Molecular and Cellular Biology "Immunopathogenesis of HIV Infection"*.
93. **Van Lint, C.**, Emiliani, S., Ott, M., & Verdin, E. (1996). Chromatin is an integral component of HIV-1 transcriptional repression and activation. *Abstract of the First Annual Meeting of the Molecular Medicine Society*.
94. **Van Lint, C.**, Amella, C. A., John,, Jie, T., Emiliani, S., & Verdin, E. (1996). A new enhancer downstream of the transcription start site of HIV-1 is critical for virus infectivity. *Abstract of the Retroviruses Meeting*.
95. Ott, M., Emiliani, S., **Van Lint, C.**, Herbein, G., Chirmule, N., Lovett, J., Mc Closkey,, Pahwa, S., & Verdin, E. (1996). The HIV Tat protein confers hypersensitivity to CD28-mediated costimulatory signals in infected T cells.). *Abstract of the 1996 Annual Meeting of the Institute of Human Virology*.
96. Ott, M., Emiliani, S., **Van Lint, C.**, Herbein, G., Chirmule, N., Lovett, J., Mc Closkey,, Pahwa, S., & Verdin, E. (1996). The second exon of HIV-1 Tat confers hypersensitivity to CD28-mediated costimulatory signals in infected T cells.). *Abstract of the Third West Coast Retrovirus Meeting*.
97. Kiermer, V., Dequiedt, F., **Van Lint, C.**, Verdin, E., Burny, A., & Droogmans, L. (1996). The role of a potential c-Myc/Max binding site on the bovine leukemia virus long terminal repeat transcriptional activity. *Abstract of the 8th workshop on Pathogenesis of Animal Retroviruses*.
98. Kiermer, V., **Van Lint, C.**, Verdin, E., Burny, A., & Droogmans, L. (1996). The role of the RU5 region of the Bovine leukemia virus genome in the transcriptional control of viral expression. *Achives Internationales de Physiologie, de Biochimie et de Biophysique*.

1995

99. **Van Lint, C.**, Ott, M., Emiliani, S., Jie, T., & Verdin, E. (1995). Histone hyperacetylation induces HIV-1 gene expression in latently infected cell lines. *Abstract of the Retroviruses Meeting*.
100. Emiliani, S., Ott, M., **Van Lint, C.**, Jie, T., & Verdin, E. (1995). Mechanism of HIV-1 latency: a mutation in the TAR region impairs Tat responsiveness of the promoter and is complemented by TNF- α /TPA treatment. *Abstract of the Retroviruses Meeting*.
101. **Van Lint, C.**, & Verdin, E. (1995). Chromatin disruption during transcriptional activation of the integrated HIV-1 promoter. *Abstract of the 1995 FASEB Summer Research Conference on Chromatin and Transcription*.
102. **Van Lint, C.**, Emiliani, S., Ott, M., & Verdin, E. (1995). Histone hyperacetylation causes the disruption of a single nucleosome in the HIV-1 promoter and transcriptional activation. *Abstract of the Fourteenth Summer Symposium in Molecular Biology "Chromosomal Controls of Gene Expression"*.
103. **Van Lint, C.**, Emiliani, S., Ott, M., & Verdin, E. (1995). Histone hyperacetylation causes the disruption of a single nucleosome in the HIV-1 promoter and transcriptional activation. *Abstract of the Cold Spring Harbor Meeting on Cancer Cells "Mechanisms of Eukaryotic Transcription"*.
104. **Van Lint, C.**, Ghysdael, J., Vanhulle, C., Paras, P., Burny, A., & Verdin, E. (1995). A transcriptional regulatory element is associated with a nuclease-hypersensitive site in the pol gene of HIV-1. *Abstract of the Baxter Nobel Symposium on "Molecular design for life"*.

1994

105. **Van Lint, C.**, Ghysdael, J., Vanhulle, C., Paras, P., Burny, A., & Verdin, E. (1994). A transcriptional regulatory region is associated with a nuclease hypersensitive site in the pol gene of HIV-1 in a promonocytic cell line. *Abstract of the Annual Meeting of the N.I.H. Laboratory of Tumor Cell Biology*.

1993

106. Verdin, E., Paras, P., El Kharroubi, A., & **Van Lint, C.** (1993). In vivo footprinting of the HIV-1 LTR identifies a chromatin disruption associated with promoter activation. *Abstract of the 1993 Cold Spring Harbor Laboratory: Retroviruses Meeting*.
107. Verdin, E., Paras, P., El Kharroubi, A., & **Van Lint, C.** (1993). HIV-1 promoter activation is accompanied by the disruption of a nucleosome in the TAR region. *Abstract of the 5th International Conference of the NCDDG-HIV: coordinated therapies for HIV infection*.
108. **Van Lint, C.**, Ghysdael, J., Paras, P., Burny, A., & Verdin, E. (1993). A transcriptional regulatory region is associated with a nuclease hypersensitive site in the pol gene of HIV-1 in a promonocytic cell line. *Abstract of the 4th Rhine-Main Symposium on HIV and macrophages: functions of macrophages and accessory cells in HIV and other lentivirus infections..*

109. **Van Lint, C.**, Ghysdael, J., Paras, P., Burny, A., & Verdin, E. (1993). Several DNA-binding proteins bind to the intragenic enhancer located in the pol gene of HIV-1. *Abstract of the 5th International Conference of the NCDDG-HIV: coordinated therapies for HIV infection.*
110. **Van Lint, C.**, Ghysdael, J., Paras, P., Burny, A., & Verdin, E. (1993). A T-lymphoid- and monocyte/macrophage transcriptional enhancer is associated with a DNase I hypersensitive site in the pol gene of HIV-1. *Abstract of the 1993 Cold Spring Harbor Laboratory: Retroviruses Meeting.*

1990

111. Verdin, E., Becker, N. G., **Van Lint, C.**, & Burny, A. (1990). Identification and characterization of a transcriptional enhancer in the pol gene of HIV-1. *Abstract of the 1990 Cold Spring Harbor Laboratory: RNA Tumor Viruses Meeting.*
112. Verdin, E., **Van Lint, C.**, & Burny, A. (1990). The intragenic enhancer of HIV-1 contains functional AP-1 binding sites. *Abstract of the 1990 Annual Meeting of the NIH Laboratory of Tumor Cell Biology of the National Cancer Institute.*

5.1.8. - Rapports, comptes rendus, notes de lecture et lettres à l'éditeur, working papers

1996

1. Burny, A., Bex, F., & **Van Lint, C.** (1996). Aids science: A field in the S phase. *Cellular pharmacology*, 3, 261-262.

5.2.2. - Participations actives à des congrès et colloques internationaux

2015

1. Van Driessche, B., Rodari, A., Delacourt, N., Vanhulle, C., & **Van Lint, C.** (2015). *Study of RNA polymerase II-mediated and RNA polymerase III-mediated transcriptions of Bovine Leukemia Virus (BLV)*. Publication présentée à la conférence 1st Molecular Microbiology Mornings (Gosselies, Belgium).

5.2.7. - Autres (collaborations nationales et internationales, dépôt de brevets, etc.)

2014

1. **Van Lint, C.**, Darcis, G., & Kula, A. (2014, juillet 24). *Methods and compositions for synergistic activation of retroviral expression.*

2013

2. Bouchat, S., Gatot, J.-S., Rohr, O., & **Van Lint, C.** (2013, avril 11). *Reactivation of HIV-1 gene expression to treat persistent HIV infection: WO2013050422.*

2005

3. Boland, S., Bollen, A., Burny, A., Cauvin, C., De Walque, S., Demonte, D., Durant, F., Georges, B., Hevesi, L., Jacquet, A., Le Van, K., & **Van Lint, C.** (2005, mars 31). 2-Pyridinone derivatives, having HIV inhibiting properties: WO2005028442 A2.

2003

4. **Van Lint, C.**, Burny, A., Quivy, V., & Adam, E. (2003, juillet 03). *METHOD FOR OBTAINING THE ELIMINATION OF INTEGRATED AND FUNCTIONAL VIRUSES FROM INFECTED MAMMAL CELLS: WO Patent WO/2003/053468, 2003.*

Thèses et mémoires

2002

1. **Van Lint, C.** (2002). *Etude de la régulation transcriptionnelle du virus de l'immunodéficience humaine de type 1 (HIV-1): rôle de l'acétylation des histones et rôle de la protéine virale trans-activatrice tat* (Thèse doctorale non-publiée). Université libre de Bruxelles, Faculté des sciences, Bruxelles.

1994

2. **Van Lint, C.** (1994). *Etudes de la régulation transcriptionnelle du virus hiv-1 : caractérisation d'un élément de régulation intragénique et analyse de la structure chromatinienne dans la région promotrice* (Thèse doctorale non-publiée). Université libre de Bruxelles, Faculté des sciences, Bruxelles.